This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.
As the leading independent source of news in oncology, The Cancer Letter has decided that it is our moral imperative to provide coverage of COVID-19 free of charge until this crisis is resolved.
On a recent call with directors of cancer centers, NCI Director Ned Sharpless reminded us that quarantines present opportunities for scientists to think deeply.
The phase III VIALE-A study demonstrated that Venclexta in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukemia who were ineligible for intensive induction chemotherapy, compared to azacitidine alone.
Highly focused, intense doses of radiation called stereotactic ablative radiation may slow progression of disease in a subset of men with hormone-sensitive prostate cancers that have spread to a few separate sites in the body, according to results of a phase II clinical trial of the therapy.
Repurposed antidepressant may be a treatment option when prostate cancer comes back, USC study finds
An antidepressant in use for decades, repurposed to fight prostate cancer, shows promise in helping patients whose disease has returned following surgery or radiation, a pilot study at USC shows.
The COVID-19 crisis has consequences not only for those who have become infected and the doctors and nurses who care for them. The care of other patients is also threatened by the increasing stress that national health systems and societies as a whole are under.
UCLA Jonsson Comprehensive Cancer Center and UT Southwestern Simmons Comprehensive Cancer Center are the newest members of the National Comprehensive Cancer Network.
S. Michael Rothenberg has joined Pfizer as the head of Early Clinical Development at the Boulder Research Unit.
Kathleen Goss was named associate director for administration at the University of Chicago Medicine Comprehensive Cancer Center.
